(Q34199603)

31 July 2017

title

Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab (English)

1 reference

31 July 2017

Jacqueline M Benson

1

1 reference

31 July 2017

Clifford W Sachs

2

1 reference

31 July 2017

George Treacy

3

1 reference

31 July 2017

Honghui Zhou

4

1 reference

31 July 2017

Charles E Pendley

5

1 reference

31 July 2017

Carrie M Brodmerkel

6

1 reference

31 July 2017

Gopi Shankar

7

1 reference

31 July 2017

Mary A Mascelli

8

1 reference

31 July 2017

publication date

1 July 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

29

1 reference

31 July 2017

issue

7

1 reference

31 July 2017

page(s)

615-624

1 reference

Interleukin-12 and the regulation of innate resistance and adaptive immunity

31 July 2017

cites work

1 reference

Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones

21 January 2018

1 reference

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

21 January 2018

1 reference

A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits

21 January 2018

1 reference

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

21 January 2018

1 reference

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

21 January 2018

1 reference

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

21 January 2018

1 reference

Increased release of interleukin-12p40 in MS: association with intracerebral inflammation

21 January 2018

1 reference

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice

21 January 2018

1 reference

Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab

21 January 2018

1 reference

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

21 January 2018

1 reference

A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R

21 January 2018

1 reference

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17

21 January 2018

1 reference

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

21 January 2018

1 reference

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

21 January 2018

1 reference

Development, cytokine profile and function of human interleukin 17-producing helper T cells

21 January 2018

1 reference

Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells

21 January 2018

1 reference

Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells.

21 January 2018

1 reference

Effector T cell plasticity: flexibility in the face of changing circumstances

21 January 2018

1 reference

Plasticity of CD4+ T cell lineage differentiation.

21 January 2018

1 reference

IL-23 promotes the production of IL-17 by antigen-specific CD8 T cells in the absence of IL-12 and type-I interferons.

21 January 2018

1 reference

IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NK-like T cell function differentially from IL-12

21 January 2018

1 reference

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

21 January 2018

1 reference

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

21 January 2018

1 reference

Interleukin-12, interleukin-23, and psoriasis: current prospects

21 January 2018

1 reference

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

21 January 2018

1 reference

Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.

21 January 2018

1 reference

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

21 January 2018

1 reference

The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans

21 January 2018

1 reference

Comorbidities in patients with psoriasis

21 January 2018

1 reference

Reproductive/developmental toxicity and immunotoxicity assessment in the nonhuman primate model

21 January 2018

1 reference

An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.

21 January 2018

1 reference

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis

21 January 2018

1 reference

Transcytosis and catabolism of antibody

21 January 2018

1 reference

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?

21 January 2018

1 reference

Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies

21 January 2018

1 reference

21 January 2018

1 reference

Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases

21 January 2018

1 reference

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

Immunogenicity of therapeutic proteins: clinical implications and future prospects

21 January 2018

1 reference

Pathogenesis and therapy of psoriasis

21 January 2018

1 reference

Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy

21 January 2018

1 reference

Suppression of lymphoma and epithelial malignancies effected by interferon gamma

21 January 2018

1 reference

A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage

21 January 2018

1 reference

The role of IL-12, IL-23 and IFN-gamma in immunity to viruses

21 January 2018

1 reference

The role of interleukin-12 in human infectious diseases: only a faint signature

21 January 2018

1 reference

Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features

21 January 2018

1 reference

Oesophageal squamous cell carcinoma in a young adult with IL-12R beta 1 deficiency

21 January 2018

1 reference

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis

21 January 2018

1 reference

12 December 2020

T(H)-17 differentiation: of mice and men

1 reference

12 December 2020

Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy

1 reference

12 December 2020

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production

1 reference

12 December 2020

IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice

1 reference

12 December 2020

Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease

1 reference

12 December 2020

Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis

1 reference

12 December 2020

Presence and modulation of interleukin-12 in seminal plasma of fertile and infertile men.

1 reference

12 December 2020

IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder

1 reference

12 December 2020

IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination

1 reference

12 December 2020

Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation.

1 reference

12 December 2020

A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis

1 reference

12 December 2020

Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis

1 reference

12 December 2020

Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells

1 reference

12 December 2020

Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

1 reference

12 December 2020

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

12 December 2020

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins

1 reference

12 December 2020

Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.

1 reference

12 December 2020

Expression of interleukin-12 is increased in psoriatic skin

1 reference

12 December 2020

IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs

1 reference

12 December 2020

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis

1 reference

12 December 2020

A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis

1 reference

12 December 2020

Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions

1 reference

12 December 2020

Monoclonal antibody pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NBT.1903

1 reference

31 July 2017

1 reference